Kerry and Kameda Seika announce new exclusive licensing agreement for Japanese rice-derived postbiotic

Kameda has extensively researched rice-based lactobacillus for over 25 years and has accumulated several health claims

Kerry has announced a new commercial agreement with Japan-based Kameda Seika to market and distribute the company’s rice-derived postbiotic exclusively in Americas and Europe across a range of applications.

Kameda Seika is a leading global rice cracker company with decades of rice research experience. Kameda’s postbiotic Lactobacillus K-1 (Lactobacillus casei subsp, 327) has been scientifically proven to improve both digestive and skin health and can be used in a variety of food, beverages and supplements.

Kerry will drive the commercialisation of this new technology to reach consumers outside of Japan by leveraging the full breadth of the company’s technology portfolio, application expertise and commercial footprint.

Commenting on the new agreement, Dan Benson, Applied Health and Nutrition Lead for Kerry APMEA, said: “As lifespans increase globally, the search is on to find innovative and sustainable solutions which will help consumers to stay active and healthy for as long as possible. This new postbiotic is a premium science backed ingredient that builds on our core strengths in digestive and immune health.”

Commenting on the agreement, Dr Lekh Juneja, Chairman CEO Kameda Seika said: “Kerry is an ideal partner, with deep expertise in science backed branded ingredients, including probiotics and postbiotics, and their footprint and presence of dedicated innovation and application centers of excellence across the globe.”

Image credit- shutterstock

Read Previous

Fonterra and Nestlé to sell DPA Brazil joint venture for NZD $210 M

Read Next

WeighPack launches two state-of-the-art packaging machines for bulk bagging

Leave a Reply